{"id":483188,"date":"2020-05-07T22:34:01","date_gmt":"2020-05-07T22:34:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=483188"},"modified":"2020-05-07T22:34:01","modified_gmt":"2020-05-07T22:34:01","slug":"actinic-keratosis-market-insights-epidemiology-and-market-forecast2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/actinic-keratosis-market-insights-epidemiology-and-market-forecast2030_483188.html","title":{"rendered":"Actinic Keratosis Market Insights, Epidemiology and Market Forecast-2030"},"content":{"rendered":"
\"Actinic<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Actinic Keratosis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Actinic Keratosis , historical and forecasted epidemiology as well as the Actinic Keratosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

DelveInsight’s “Actinic Keratosis – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>” report delivers an in-depth understanding of the Actinic Keratosis , historical and forecasted epidemiology as well as the Actinic Keratosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the report<\/strong>
1. The United States had the highest Actinic Keratosis prevalence with 66,733,101 cases in 2017.
2. The male-to-female ratios of Actinic Keratosis patients differ among various countries, but a male excess is a consistent finding among all countries except Italy.
3. Among the EU5 countries, Germany had the highest Actinic Keratosis prevalent population with 8,294,972 cases followed by the United Kingdom with a prevalent population of 5,419,455 in 2017. On the other hand, Japan has the lowest prevalent population with 700,954 cases in 2017.<\/p>\n

 <\/p>\n

\"\"<\/span><\/p>\n

“Actinic Keratosis prevalence is higher among men than women of the same age.” <\/strong><\/p>\n

Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/actinic-keratosis-market<\/a><\/strong><\/p>\n

The launch of the emerging therapies is expected to significantly impact Actinic Keratosis treatment scenario in the upcoming years:-<\/strong>
<\/strong>Drugs covered
1. KX01 Ointment
2. VDA-1102
3. SOR 007
And many others<\/p>\n

<\/strong>The key players in Actinic Keratosis market are:<\/strong>
<\/strong>1. Athenex
2. Vidac Pharma
3. DFB Soria<\/p>\n

And many others<\/p>\n

<\/strong>Table of contents<\/strong><\/p>\n

<\/strong>1. Key Insights
2. Executive Summary of Actinic Keratosis
3. Actinic Keratosis Market Overview at a Glance
4. Actinic Keratosis Disease Background and Overview
5. Actinic Keratosis Epidemiology and Patient Population
6. Country Wise-Epidemiology of Actinic Keratosis Disease
6.1. United States
6.2. EU5 Countries
6.3. Germany
6.4. France
6.5. Italy
6.6. Spain
6.7. United Kingdom
6.8. Japan
7. Actinic Keratosis Treatment Practices
8. Current Unmet Needs
9. Actinic Keratosis Marketed Drugs
9.1. Aldara: Bausch Health Companies (Formerly known as Valeant Pharmaceuticals)
9.2. Zyclara: Bausch Health Companies (Formerly known as Valeant Pharmaceuticals)
9.3. Solaraze: Sandoz Pharmaceuticals
9.4. Efudex: Bausch Health Companies (Formerly known as Valeant Pharmaceuticals)
9.5. Carac: Bausch Health Companies (Formerly known as Valeant Pharmaceuticals)
9.6. Picato: LEO Pharma
9.7. Actikerell: Almirall S.A.
9.8. Fluoroplex: Aqua Pharmaceuticals
9.9. Ameluz: Biofrontera
9.10.Metvixia: Galderma
9.11.Levulan Kerastick: DUSA Pharmaceuticals
9.12.Alacare: Photonamic GmbH & Co. KG
9.13.Eryfotona AK-NMSC SPF 100+ Fluid: ISDIN Corp
10. Key Cross Competition
11. Actinic Keratosis Emerging Drugs
11.1.KX01 Ointment: Athenex
11.2.VDA-1102: Vidac Pharma
11.3.SOR 007: DFB Soria
12. Actinic Keratosis 7 Major Market Analysis
13. The United States Market Outlook of Actinic Keratosis
14. EU-5 Countries: Market Outlook
15. Germany Market outlook of Actinic Keratosis
16. France Market outlook of Actinic Keratosis
17. Italy Market outlook of Actinic Keratosis
18. Spain Market outlook of Actinic Keratosis
19. United Kingdom Market outlook of Actinic Keratosis
20. Japan Market outlook of Actinic Keratosis
21. Market Drivers
22. Market Barriers
23. SWOT Analysis
24. Reimbursement
25. KOL Views
26. Appendix
27. DelveInsight Capabilities
28. Disclaimer
29. About DelveInsight<\/p>\n

<\/strong>About DelveInsight<\/strong>
<\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight’s “Actinic Keratosis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Actinic Keratosis , historical and forecasted epidemiology as well as the Actinic Keratosis market trends in the United States, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,412,406,404],"tags":[],"class_list":["post-483188","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-News-Current-Affairs","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/483188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=483188"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/483188\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=483188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=483188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=483188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}